Matching trials
2,411 results
- Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men: Complete Statistical AnalysisIndependent statistical analysis of Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BioCSI-2Independent statistical analysis of Biomarkers of Cockroach Sublingual Immunotherapy 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01380327).
- BIRCHIndependent statistical analysis of A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with…
- Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Bladder Scan of Residual Urine With New Catheter: Complete Statistical AnalysisIndependent statistical analysis of Bladder Scan of Residual Urine With New Catheter: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01048541).
- Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts: Complete Statistical AnalysisIndependent statistical analysis of Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia: Complete Statistical AnalysisIndependent statistical analysis of Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BLIR-HIVIndependent statistical analysis of Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01228318).
- Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission: Complete Statistical AnalysisIndependent statistical analysis of Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BMS 247550 to Treat Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of BMS 247550 to Treat Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00030992).
- BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- BOLTIndependent statistical analysis of A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor: Complete Statistical AnalysisIndependent statistical analysis of Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Booster Dose Trial: Complete Statistical AnalysisIndependent statistical analysis of Booster Dose Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05016622).
- BOREASIndependent statistical analysis of Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- BortezomibIndependent statistical analysis of Bortezomib to Treat Significant Complication of HSCT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01929980).
- Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00869323).
- Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00075881).
- Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL): Complete Statistical AnalysisIndependent statistical analysis of Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00440726).
- Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence…
- Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin’s Lymphoma That is Recurrent or Did Not Respond to Previous Therapy: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy: primary endpoint results, effect estimate with…
- BOSTON-4Independent statistical analysis of A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bosutinib in Adult Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Bosutinib in Adult Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01331291).
- BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02230956).
- BOTOX® for the Treatment of Platysma Prominence: Complete Statistical AnalysisIndependent statistical analysis of BOTOX® for the Treatment of Platysma Prominence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03915067).
- Botulin-A Toxin Instillations and Overactive Bladder: Complete Statistical AnalysisIndependent statistical analysis of Botulin-A Toxin Instillations and Overactive Bladder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00583219).
- Botulinum Toxin A to Treat Arm Tremor: Complete Statistical AnalysisIndependent statistical analysis of Botulinum Toxin A to Treat Arm Tremor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02207946).
- Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia: Complete Statistical AnalysisIndependent statistical analysis of Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BRAiN-MIndependent statistical analysis of Bringing Relief to Adolescents Naturally Using Melatonin for Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02344316).
- BRAVE-EPAIndependent statistical analysis of Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02719327).
- Break MBIndependent statistical analysis of A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Breast Cancer Risk Biomarkers in Postmenopausal Women: Complete Statistical AnalysisIndependent statistical analysis of Breast Cancer Risk Biomarkers in Postmenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01252290).
- BretuximabIndependent statistical analysis of Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BridgeIndependent statistical analysis of Maintenance of Platelet Inhibition With Cangrelor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00767507).
- Brigatinib Before Brain Irradiation Trial (B3i Trial): Complete Statistical AnalysisIndependent statistical analysis of Brigatinib Before Brain Irradiation Trial (B3i Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04634110).
- Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BrTK02Independent statistical analysis of Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bryostatin Treatment of Moderately Severe Alzheimer’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Bryostatin Treatment of Moderately Severe Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04538066).
- BSSIndependent statistical analysis of Blue Sky Study: Impact of Milk and Vitamin D for Child Growth and Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL): Complete Statistical AnalysisIndependent statistical analysis of BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis: Complete Statistical AnalysisIndependent statistical analysis of Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04251819).
- Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…